Inhibrx Biosciences (INBX) Receivables - Net (2023 - 2025)

Inhibrx Biosciences (INBX) has reported Receivables - Net for 3 consecutive years, with $237000.0 the latest figure, recorded in Q2 2025.

• In Q2 2025, Receivables - Net rose 44.51% year-over-year to $237000.0; the TTM figure through Jun 2025 stood at $237000.0 (up 44.51% YoY), while the FY2025 annual figure was $23000.0, down 88.5% from the prior year.
• Receivables - Net advanced to $237000.0 in Q2 2025 per INBX's latest filing, from $200000.0 in the prior quarter.
• Across five years, Receivables - Net topped out at $778000.0 in Q4 2023 and bottomed at $164000.0 in Q2 2024.
• Historically, Receivables - Net has averaged $410200.0 across 3 years, with a median of $237000.0 in 2025.
• Annual changes were most pronounced in 2024 — Receivables - Net tumbled 74.29% — and 2025, when it surged 44.51%.
• Inhibrx Biosciences' Receivables - Net stood at $778000.0 in 2023, then sank by 74.29% to $200000.0 in 2024, then climbed by 18.5% to $237000.0 in 2025.
• Business Quant data shows INBX's Receivables - Net at $237000.0 in Q2 2025, $200000.0 in Q4 2024, and $672000.0 in Q3 2024.